肿瘤引流淋巴结在免疫治疗中的作用研究进展  

Development in immunotherapy of tumor draining lymph node

作　　者：董小锋[1] 杨建荣[1] 李朋洋 钟敬涛 Dong Xiaofeng;Yang Jianrong;Li Pengyang;Zhong Jingtao(Department of Hepatobiliary,Pancreas and Spleen Surgery,the People’s Hospital of Guangxi Zhuang Autonomous Region,Nanning 530021,China;Department of Hepatobiliary Surgery,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250117,China)

机构地区：[1]广西壮族自治区人民医院肝胆胰脾外科,南宁530021 [2]山东省肿瘤防治研究院(山东省肿瘤医院)肝胆外科,山东第一医科大学(山东省医学科学院),济南250117

出　　处：《中华实验外科杂志》2024年第2期406-408,共3页Chinese Journal of Experimental Surgery

基　　金：国家自然科学基金(82160589);山东省自然科学基金(ZR2023MH044);南宁市青秀区科学技术局重点研发计划(2020035)。

摘　　要：肿瘤引流淋巴结(TDLN)是位于肿瘤下游的第一站淋巴结, 也被称为前哨淋巴结, TDLN内免疫微环境改变引起免疫细胞活性的变化直接影响肿瘤细胞的活性及远处转移能力。免疫治疗目前是恶性肿瘤治疗的重要手段, TDLN内免疫微环境的变化与肿瘤免疫治疗的效果密切相关。本文就TDLN内免疫微环境的变化与肿瘤免疫治疗疗效的进展进行总结, 为恶性肿瘤的免疫治疗提供思路。The tumor draining lymph node(TDLN)is the first lymph node located downstream of the tumor,also known as the sentinel lymph node.Immune cell activity changes caused by changes of immune microenvironment within TDLN directly impact the activity and the metastatic ability of tumor cells.Immunotherapy is currently an important therapy for the treatment of malignant tumors,and changes in the immune microenvironment within TDLN are closely related to the effectiveness of tumor immunotherapy.This paper summarizes the progress in the changes of the immune microenvironment within TDLN and the efficacy of tumor immunotherapy,providing new ideas for the immunotherapy of malignant tumors.

关 键 词：恶性肿瘤 淋巴结 免疫治疗 

分 类 号：R730.51[医药卫生—肿瘤]